Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | CA6 | P23280 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | TPMT | P51580 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29892240 | 1.00 | KDM4E (0.59) | KDM4EHTTRAB9ATSHRNPC1 | |
| SCHEMBL10780177 | 0.93 | KDM4E (0.56) | KDM4EHTTRAB9ATSHRNPC1 | |
| SCHEMBL142851 | 0.91 | PDE4D (0.54) | KDM4EHTTRAB9ATSHRNPC1 | |
| SCHEMBL2564619 | 0.87 | CA12 (0.71) | KDM4EHTTRAB9ATSHRNPC1 | |
| SCHEMBL16959609 | 0.86 | KDM4E (0.55) | KDM4EHTTRAB9ATSHRNPC1 | |
| SCHEMBL3738587 | 0.85 | MAPT (0.64) | KDM4EHTTRAB9ATSHRNPC1 | |
| SCHEMBL4696721 | 0.85 | KDM4E (0.58) | KDM4EHTTRAB9ATSHRNPC1 | |
| SCHEMBL29824542 | 0.85 | KDM4E (0.61) | KDM4EHTTRAB9ATSHRNPC1 | |
| SCHEMBL5466423 | 0.85 | ALDH1A1 (0.56) | RAB9ATSHRNPC1SMN1; SMN2TP53 | |
| SCHEMBL29399077 | 0.84 | TSHR (0.73) | TSHRSMN1; SMN2MAPK1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230013304-A1 | N2-ARYLMETHYL-4-HALOALKYL-PYRIDAZIN-3-ONE CFTR MODULATORS FOR THE TREATMENT OF CYSTIC FIBROSIS | ECOLE NORMALE SUPERIEURE DE LYON (FR) | 2023-01-19 | — | — | US | disclosed |
| WO-2021105641-A1 | N2-ARYLMETHYL-4-HALOALKYL-PYRIDAZIN-3-ONE CFTR MODULATORS FOR THE TREATMENT OF CYSTIC FIBROSIS | UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE (FR) | 2021-06-03 | — | — | WO | disclosed |
| CN-107148271-A | Fluorinated pyridazin-3-one compounds for the treatment of pulmonary diseases | 法国兰斯大学 | 2017-09-08 | — | — | CN | disclosed |
| EP-3212190-A1 | FLUORINATED PYRIDAZIN-3-ONES FOR THE USE THEREOF IN THE TREATMENT OF LUNG DISEASES | Université De Reims Champagne-Ardenne (FR) | 2017-09-06 | — | — | EP | disclosed |
| US-20170247335-A1 | FLUORINATED PYRIDAZIN-3-ONES FOR THE USE THEREOF IN THE TREATMENT OF LUNG DISEASES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-08-31 | — | — | US | disclosed |
| WO-2016066973-A1 | FLUORINATED PYRIDAZIN-3-ONES FOR THE USE THEREOF IN THE TREATMENT OF LUNG DISEASES | UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE (FR) | 2016-05-06 | — | — | WO | disclosed |
| EP-0466408-B1 | N-aryl-3-aryl-4-substituted-4,5-dihydro-1H-pyrazole-1-carboxamides and processes for their production | ROHM & HAAS (US) | 2000-01-12 | — | — | EP | disclosed |
| US-5798311-A | INSECTICIDES | ROHM AND HAAS COMPANY (US) | 1998-08-25 | — | — | US | disclosed |
| EP-0466408-A1 | N-aryl-3-aryl-4-substituted-4,5-dihydro-1H-pyrazole-1-carboxamides and processes for their production | ROHM AND HAAS COMPANY (US) | 1992-01-15 | — | — | EP | disclosed |
| US-4665074-A | CARDIOTONIC, BRONCHOSPASMOLYTIC | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1987-05-12 | — | — | US | disclosed |
| EP-0163965-A2 | Pyridazinones, their preparation and use, medicaments containing pyridazinones | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1985-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013304-A1 | N2-ARYLMETHYL-4-HALOALKYL-PYRIDAZIN-3-ONE CFTR MODULATORS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, CLCN2, SCNN1B | KDM4E 4471/4885HTT 2276/4885RAB9A 1979/4885 |
| US-20170247335-A1 | FLUORINATED PYRIDAZIN-3-ONES FOR THE USE THEREOF IN THE TREATMENT OF LUNG DISEASES | PEX3, NCOA3, NCAPD3 | KDM4E 4650/4885HTT 3609/4885RAB9A 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.